Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for COVID-19 pneumonia (multicenter Italian phase 2 study)
2020-001110-38Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in coronavirus pneumonia and pneumonia, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Mortality rate one month after registration. Started Mar 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus pneumoniapneumonia
Beyond the preview
Go deeper on 2020-001110-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001110-38.